(3R)-3-[(R)-(1-fluoronaphthalen-2-yl)(5-methyl-2H-tetrazol-2-yl)methyl]piperidine | 1198799-70-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: (3R)-3-[(R)-(1-fluoronaphthalen-2-yl)(5-methyl-2H-tetrazol-2-yl)methyl]piperidine
• 英文别名: (3R)-3-[(R)-(1-fluoronaphthalen-2-yl)-(5-methyltetrazol-2-yl)methyl]piperidine
• CAS: 1198799-70-0
• 化学式: C₁₈H₂₀FN₅
• 分子量: 325.389
• InChiKey: SHEKEBXFAYAAGU-RDTXWAMCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• 3 or 4-Substituted Piperidine Compounds
  申请人：Lee Ki-Ho

  公开号：US20090306140A1

  公开（公告）日：2009-12-10

  There are disclosed racemic or enantiomerically enriched 3- or 4-substituted piperidine compounds represented by the following structural formula (I) or any of their isomers, or pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions containing the subject compounds. The subject compounds are useful for the treatment of diseases of the central nervous system, particularly depression, anxiety and pain disorder

  以下结构式（I）所表示的外消旋或对映富集的3-或4-取代哌啶化合物及其异构体或药学上可接受的盐被公开。还公开了含有这些化合物的药物组合物。这些化合物可用于治疗中枢神经系统疾病，特别是抑郁症、焦虑症和疼痛障碍。
• 3 OR 4-SUBSTITUTED PIPERIDINE COMPOUNDS
  申请人：Lee Ki-Ho

  公开号：US20120122927A1

  公开（公告）日：2012-05-17

  There are disclosed racemic or enantiomerically enriched 3- or 4-substituted piperidine compounds represented by the following structural formula (I): or any of their isomers, or pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions containing the subject compounds. The subject compounds are useful for the treatment of diseases of the central nervous system, particularly depression, anxiety and pain disorder

  本发明揭示了以下结构式（I）所示的外消旋或对映富集的3-或4-取代哌啶化合物，或其任何异构体或药学上可接受的盐。还揭示了包含该化合物的制药组合物。该化合物可用于治疗中枢神经系统疾病，特别是抑郁症、焦虑症和疼痛障碍。
• 3- OR 4-SUBSTITUTED PIPERIDINE COMPOUNDS
  申请人：SK Holdings Co., Ltd.

  公开号：EP2283000A2

  公开（公告）日：2011-02-16
• JP2011522041A
  申请人：——

  公开号：JP2011522041A

  公开（公告）日：2011-07-28
• Treatment for Substance Use Disorders and Stress Disorders
  申请人：Baylor College of Medicine

  公开号：US20140249183A1

  公开（公告）日：2014-09-04

  Treatments are described for stress disorders and substance use disorders, for example, substance use disorders associated with use of alcohol, cocaine, amphetamines, and the like.